Papers of the Week

The delta opioid receptor (DOPr) is an emerging target for the management of chronic pain and depression. Studies have highlighted the potential of biased signaling, the preferential activation of one signaling pathway over another downstream of DOPr, to generate a better therapeutic profile. BMS 986187 is a recently discovered positive allosteric modulator (PAM) of the DOPr. Here we ask if BMS 986187 can directly activate the receptor from an allosteric site in the absence of orthosteric ligand and if a signaling bias is generated.